Panbela Therapeutics Future Growth
Future criteria checks 0/6
Panbela Therapeutics se prevé un crecimiento anual de los beneficios y los ingresos de 45.8% y 73.5%, respectivamente, mientras que el BPA aumentará de grow a 77.2%.
Key information
46.1%
Earnings growth rate
82.7%
EPS growth rate
| Biotechs earnings growth | 32.5% |
| Revenue growth rate | 73.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 Apr 2024 |
Recent future growth updates
No updates
Recent updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 15 | -37 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -35 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -27 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -34 | -25 | -25 | N/A |
| 9/30/2023 | N/A | -24 | -27 | -27 | N/A |
| 6/30/2023 | N/A | -20 | -22 | -22 | N/A |
| 3/31/2023 | N/A | -36 | -21 | -21 | N/A |
| 12/31/2022 | N/A | -35 | -16 | -15 | N/A |
| 9/30/2022 | N/A | -34 | -13 | -13 | N/A |
| 6/30/2022 | N/A | -31 | -13 | -12 | N/A |
| 3/31/2022 | N/A | -12 | -10 | -10 | N/A |
| 12/31/2021 | N/A | -10 | -7 | -7 | N/A |
| 9/30/2021 | N/A | -7 | -6 | -6 | N/A |
| 6/30/2021 | N/A | -7 | -6 | -6 | N/A |
| 3/31/2021 | N/A | -5 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -5 | -4 | -4 | N/A |
| 9/30/2020 | N/A | -5 | -4 | -4 | N/A |
| 6/30/2020 | N/A | -5 | -3 | -3 | N/A |
| 3/31/2020 | N/A | -6 | -3 | -3 | N/A |
| 12/31/2019 | N/A | -6 | -3 | -3 | N/A |
| 9/30/2019 | N/A | -6 | -2 | -2 | N/A |
| 6/30/2019 | N/A | -6 | -2 | -2 | N/A |
| 3/31/2019 | N/A | -6 | -3 | -3 | N/A |
| 12/31/2018 | N/A | -6 | -2 | -2 | N/A |
| 9/30/2018 | N/A | -7 | -3 | -3 | N/A |
| 6/30/2018 | N/A | -8 | -3 | -3 | N/A |
| 3/31/2018 | N/A | -7 | -3 | -3 | N/A |
| 12/31/2017 | N/A | -10 | -3 | -3 | N/A |
| 9/30/2017 | N/A | -10 | N/A | -3 | N/A |
| 6/30/2017 | N/A | -10 | N/A | -4 | N/A |
| 3/31/2017 | N/A | -10 | N/A | -3 | N/A |
| 12/31/2016 | N/A | -5 | N/A | -2 | N/A |
| 9/30/2016 | N/A | -4 | N/A | -2 | N/A |
| 6/30/2016 | N/A | -3 | N/A | -2 | N/A |
| 3/31/2016 | N/A | -4 | N/A | -4 | N/A |
| 12/31/2015 | N/A | -5 | N/A | -4 | N/A |
| 9/30/2015 | N/A | -5 | N/A | -4 | N/A |
| 6/30/2015 | N/A | -6 | N/A | -4 | N/A |
| 3/31/2015 | N/A | -5 | N/A | -4 | N/A |
| 12/31/2014 | N/A | -4 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: X70 se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios frente mercado: X70 se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: X70 se prevé que siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: X70 no tendrá ingresos el año que viene.
Ingresos de alto crecimiento: X70 no tendrá ingresos el año que viene.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de X70 se prevé elevada dentro de 3 años.